(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on precision medicine, biologics, gene and cell therapies, supported by better diagnosis, regulatory incentives, partnerships and localized manufacturing.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Orphan Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Orphan Drugs Market Projected to Reach $794.12 Billion by 2030 as Rare Disease Research Accelerates
The global orphan drugs market is experiencing rapid expansion, supported by rising investment in rare disease treatments, favorable regulatory policies and continued advances in biotechnology. The market is expected to grow from $229.71 billion in 2025 to $293.6 billion in 2026, representing a compound annual growth rate (CAGR) of 27.8%.
Historic growth has been supported by the implementation of orphan drug legislation, government incentives and research grants. Increasing patient advocacy, limited treatment options and significant unmet medical needs have also encouraged pharmaceutical and biotechnology companies to expand their rare disease development programs.
The orphan drugs market is forecast to reach $794.12 billion by 2030, advancing at a CAGR of 28.2%. Key growth drivers include progress in genomics, higher rare disease diagnosis rates, increased development of biologic orphan drugs and broader access through specialty distribution channels. Investment in niche therapeutics is also expected to strengthen the global pipeline of treatments for underserved patient populations.
Major orphan drugs market trends include the expansion of precision medicine, increased regulatory support for orphan drug approvals and rising development activity in gene and cell therapies. Strategic collaborations between pharmaceutical and biotechnology businesses are helping organizations share research expertise, accelerate clinical programs and improve the commercialization of advanced therapies.
The increasing prevalence and recognition of rare diseases remain central to market growth. Reliable cold-chain logistics and temperature-controlled distribution are particularly important for many biologic treatments, although access to this infrastructure varies by location. Expanding diagnostic capabilities and greater awareness among healthcare professionals are helping identify more patients who may benefit from targeted therapies.
Broader demand for specialized oncology treatments is also contributing to the need for continued therapeutic innovation. In January 2025, the American Cancer Society estimated that 59,660 new cases of oral cavity and oropharyngeal cancer would be diagnosed in the United States during 2025, with approximately 12,770 deaths anticipated. The continuing burden of serious and difficult-to-treat diseases reinforces the importance of developing more targeted treatment options.
Companies participating in the orphan drugs market are increasingly pursuing regulatory approvals for advanced therapies, including CAR T-cell treatments. These programs can address urgent medical needs while benefiting from incentives intended to support research and innovation for rare conditions.
In March 2024, Cabaletta Bio received orphan drug designation from the US Food and Drug Administration for CABA-201, an investigational CAR T-cell therapy targeting CD19-positive B cells. The candidate is being developed to induce durable remission in autoimmune diseases, including systemic sclerosis. Its potential benefits include targeted activity and the possibility of lasting results following a single infusion.
Merger and acquisition activity is also strengthening rare disease pipelines. In May 2024, Sanofi acquired Inhibrx Inc. for $1.7 billion. The transaction was intended to advance Sanofi's work in alpha-1 antitrypsin deficiency and expand its ability to address unmet needs among patients with rare diseases. The acquisition reflects the growing strategic value of specialized biotechnology platforms and late-stage orphan drug candidates.
North America was the largest region in the global orphan drugs market in 2025, while the Middle East is expected to be the fastest-growing region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries included are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Therapy Area: Oncology; Blood; Central Nervous System; Endocrine; Cardiovascular; Respiratory; Immunomodulatory
2) By Diseases Type: Oncology; Hematology; Neurology; Cardiovascular; Other Disease Types
3) By Drug Type: Biological; Non-Biological
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Sales
Subsegments:
1) By Oncology: Targeted Therapies; Chemotherapy Agents; Immunotherapy Drugs; Hormonal Therapies
2) By Blood: Hematopoietic Growth Factors; Coagulation Factor Concentrates; Treatments for Rare Blood Disorders
3) By Central Nervous System: Medications for Rare Neurological Disorders; Antiepileptic Drugs for Rare Epilepsy Syndromes; Treatments for Rare Neurodegenerative Diseases
4) By Endocrine: Hormonal Replacement Therapies; Treatments for Rare Endocrine Disorders
5) By Cardiovascular: Medications for Rare Cardiovascular Conditions; Treatments for Rare Genetic Heart Disorders
6) By Respiratory: Therapies for Rare Respiratory Diseases; Medications for Rare Allergic Conditions
7) By Immunomodulatory: Treatments for Rare Autoimmune Disorders; Immunotherapies for Rare Inflammatory Conditions
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment